GKOS vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

GKOS

31.5
AI Score
VS
BIO Wins

BIO

59.5
AI Score

Investment Advisor Scores

GKOS

32score
Recommendation
AVOID NEW MONEY

BIO

60score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric GKOS BIO Winner
Forward P/E 1666.6667 40.6504 BIO
PEG Ratio 1.64 1.1905 BIO
Revenue Growth 58.0% 0.5% GKOS
Earnings Growth 1896.3% 18.7% GKOS
Tradestie Score 31.5/100 59.5/100 BIO
Profit Margin -24.6% 39.5% BIO
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY BUY BIO

Relative Price Performance (Last 90 Days)

GKOS 1M: +46.5% · 3M: +33.3% BIO 1M: +2.2% · 3M: +4.0%

Current Technical Phase

GKOS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 69

RSI (14): 68.9 · Price: $246.03

BIO

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope 0.2%) with fading momentum, RSI 48

RSI (14): 47.7 · Price: $370.48

Fundamentals Snapshot

Metric GKOS BIO
Market Cap — —
Forward P/E 175.7 37.4
Trailing P/E — 10.3
Revenue (TTM) — —
Revenue Growth 0.6% 0.0%
Gross Margin 0.8% 0.5%
Operating Margin -0.1% 0.1%
EPS -2.95 37.64
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.